Enolen received fast track designation for localized prostate cancer, showing promising preclinical results with high intraprostatic drug concentrations and minimal systemic exposure. Break Wave ...
Notable findings highlighted stark differences between this safety-net population and national averages.
Enolen's fast track designation by the FDA highlights its potential to address unmet needs in early-stage prostate cancer treatment. The implant technology aims to deliver high local drug ...
Tom Jayram, MD, discusses the phase 2 SURF302 trial of TYRA-300, a FGFR3-selective inhibitor for FGFR3-altered LG-IR-NMIBC. The phase 2 SURF302 trial (NCT06995677) is assessing the safety and efficacy ...
ACOU085 is a first-in-class otoprotective agent targeting cisplatin-induced hearing loss in testicular cancer patients. The PROHEAR trial is a double-blind, split-body study involving young male ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results